Background. Iron de®ciency (ID) is the main cause of hyporesponsiveness to erythropoietin in haemodialysis patients and its detection is of value since it is easily corrected by intravenous iron. Markers of iron supply to the erythron, including erythrocyte zinc protoporphyrin (Er-ZPP), percentage of hypochromic erythrocytes (Hypo), reticulocyte haemoglobin content (CHr) and soluble transferrin receptor (sTf R), may be more accurate predictors of ID than ferritin (Fer) and transferrin saturation (TSat), but relative diagnostic power and best threshold values are not yet established. Methods. In 125 haemodialysis patients on maintenance erythropoietin, the diagnostic power of the above parameters was evaluated by ROC curve, multivariate regression, and stepwise discriminant analyses. Diagnosis of ID was based on haemoglobin response to intravenous iron (992 mg as sodium ferric gluconate complex over an 8-week period). Results. Fifty-one patients were considered iron de®-cient (haemoglobin increase by 1.9"0.5 gudl) and 74 as iron replete (haemoglobin increase by 0.4"0.3 gudl). ROC curve analysis showed that all tests had discriminative ability with the following hierarchy: Hypo (area under curve Ws0.930, ef®ciency 89.6% at cutoff )6%), CHr (Ws0.798, ef®ciency 78.4% at cut-off O29 pg), sTfR (Ws0.783, ef®ciency 72.4% at cut-off )1.5 mgul), Er-ZPP (Ws0.773, ef®ciency 73.0% at cut-off )52 mmolumol haem), TSat (Ws0.758, ef®-ciency 70.4% at cut-off -19%) and ferritin (Ws0.633, ef®ciency 64.0% at cut-off -50 nguml). Stepwise discriminant analysis identi®ed Hypo as the only variable with independent diagnostic value, able to classify 87.2% of patients correctly. Additional tests did not substantially improve diagnostic ef®ciency of Hypo )6% alone. Conclusions. In haemodialysis patients on maintenance erythropoietin, Hypo )6% is the best currently available marker to identify those who will improve their response after intravenous iron. Costeffectiveness suggests that this parameter should be a ®rst-line tool to monitor iron requirements in clinical practice.
Introduction
Due to accelerated erythropoiesis coupled with ongoing dialysis-related blood losses, haemodialysis patients on maintenance erythropoietin (Epo) frequently develop iron-de®cient erythropoiesis, resulting from depletion of iron stores (absolute iron de®ciency) or failure to deliver adequate iron to bone marrow in spite of apparently appropriate iron stores (functional iron de®ciency) w1x.
The early and accurate detection of both absolute and functional iron de®ciency (ID) is important because it is the most common cause of suboptimal response to Epo, and can easily be corrected by intravenous (i.v.) iron administration, which improves response to the hormone.
The response to i.v. iron, producing either an increased erythropoietic response at a constant dose of Epo or a decrease in Epo needs, is the best criterion for a`gold standard' of iron-de®cient erythropoiesis. It is additionally the most widely accepted reference standard for clinical practice, where the most important goal is to identify subjects who need iron to optimize Epo treatment w2x.
Since traditional indices of iron status, including ferritin and transferrin saturation (TSat), are inaccurate in predicting iron-de®cient erythropoiesis during Epo therapy at any proposed cut-off level w3x, the usefulness of additional parameters, especially those allowing direct estimates of bone marrow iron availability, have been investigated.
Interest has been generated in the use of erythrocyte and reticulocyte indices, such as the percentage of hypochromic red blood cells (Hypo) and the reticulocyte haemoglobin content (CHr), made available by the¯ow cytometric haematological analysers Technicon H and ADVIA. Both assays provide direct insight into bone marrow iron supply and utilization by evaluating the degree of haemoglobinization. In addition, they can be performed simultaneously during routine blood counts with minimal or no incremental cost and no additional blood sampling.
An early study w4x in Epo-treated patients with Hypo )10% showing increased haemoglobin levels after i.v. iron with parallel reductions in hypochromia prompted the recently published European Best Practice Guidelines for the Management of Anaemia in Patients with Chronic Renal Failure to state that Hypo )10% is the most accurate marker for ID w5x. However, other studies, suggested that lower threshold values may be more appropriate w6 ±9x.
CHr has also proved to be a reliable marker of iron-de®cient erythropoiesis during Epo therapy, at cut-off values of -26 pg or -28 pg, and may be an early and more sensitive index than erythrocyte hypochromia due to the shorter life span of reticulocytes w9±11x.
The role of erythrocyte zinc protoporphyrin (Er-ZPP), an abnormal end-product of haem synthesis that accumulates during limited bone marrow iron availability, has also been evaluated as a marker of iron status. Its determination is simple, rapid, and inexpensive, although its long elimination half-life limits its usefulness in detecting rapid changes in iron status. Er-ZPP has been shown to be a better marker of iron-de®cient erythropoiesis than ferritin and TSat during Epo treatment, with a high sensitivity and speci®city at a threshold value )90 mmolumol haem w12x. However, recent studies have shown that Er-ZPP could not predict responses to i.v. iron supplementation over a wide number of cut-off levels, ranging from 50 to 110 mmolumol haem w13x.
In recent years the measurement of soluble transferrin receptor (sTf R) in serum has been proposed as a indicator of adequacy of iron supply to the erythron w14,15x. However, it may be of less value in patients on Epo therapy because increased erythropoiesis itself raises sTfR levels w16x.
Unfortunately, most studies examining serum sTf R in haemodialysis w14,17x failed to discriminate between the effects of Epo and iron de®ciency, making it dif®cult to evaluate the usefulness of sTf R as a marker of ID during Epo treatment.
In summary, it has not been clearly established whether newer indices of iron status provide better results than the traditional tests w18,19x. In addition, it is unclear which test and which threshold value is most accurate, since studies addressing diagnostic accuracy in detecting ID during Epo therapy are limited in number w7±13,20,21x and report con¯icting results.
The available data are dif®cult to interpret for two reasons. First, there is a bias in sample size, with populations too small for a meaningful statistical analysis w8±10,12x, and second, these studies used different criteria for the diagnosis of ID, ranging from inaccurate tests such as low ferritin w19,20x and TSat w20,21x to the more appropriate haemoglobin w7,8x, haematocrit w22x, and reticulocyte response to i.v. iron challenge w10,11x.
Although simultaneous evaluation of the different markers of bone marrow iron availability should provide better insight into the relative diagnostic values for ID, few studies have addressed this issue; almost all compared erythrocyte and reticulocyte indices, the majority favouring CHr w9,10,20x, while some favoured Hypo w8x and others showed no preference w18,19x.
Even fewer studies compared Er-ZPP and sTf R with erythrocyte and reticulocyte indices. Er-ZPP levels were shown to have no w13x or weak w22x correlations with Hypo and a weak correlation with sTf R w17x. The latter correlated well with Hypo w15x.
The purpose of our study was (i) to compare the diagnostic power of established tests of bone marrow iron availability (Hypo, CHr, Er-ZPP, and sTfR) and of traditional indices (ferritin and TSat) to identify iron-de®cient erythropoiesis subjects in a large unselected population of haemodialysis patients on maintenance Epo, and (ii) to identify best threshold values using the haemoglobin response to i.v. iron treatment as the`gold standard'.
To our knowledge, this is the ®rst study to simultaneously compare the diagnostic power of all the available laboratory markers of iron status in haemodialysis patients on Epo.
Subjects and methods

Patients
A cohort of 125 chronic thrice-weekly haemodialysis patients on maintenance Epo therapy from two dialysis units in Verona (Policlinico and Ospedale Civile Maggiore Hospitals) and satellite dialysis units at San Bonifacio and Valeggio Hospitals were included in the study.
Seventy-one were males and 54 females, aged 31±84 years; 104 were on bicarbonate haemodialysis with low-¯ux cellulose or synthetic membranes, 19 were on acetate-free bio®ltration with AN69 membranes, and two were on haemo®ltration using PAN membranes. All had been treated for at least 5 months with recombinant human erythropoietin alpha, 70 intravenously and 55 by the subcutaneous route.
Patients with recent bleeding episodes, need of haemotransfusions, clinically evident in¯ammatory and infectious diseases, malignancies, haemoglobinopathies, overt hyperparathyroidism (serum PTH above 500 nguml), aluminium overload (serum aluminium above 70 mguml), folate and vitamin B 12 de®ciencies (serum folate below 7.0 nmolul and B 12 below 156 pmolul respectively), intercurrent events such as bleeding or infection during the iron challenge period, were excluded from the study.
Prior to the study a majority of patients received i.v. iron as sodium ferric gluconate complex in sucrose (Ferlixit) on an as-needed basis according to TSat -20% anduor ferritin -100 nguml. No i.v. iron was provided in the 3 weeks prior to the study. The total amount of i.v. iron supplied in the 6 months prior to the study ranged from 0 to 1395 mg (median amount 475 mg).
Methods
Blood samples for laboratory testing were obtained prior to the ®rst-of-the-week haemodialysis sessions. Standard haematology parameters, including reticulocyte count and erythrocyte and reticulocyte indices were assayed on the Advia 120 haematology analyser (Bayer Diagnostics, Germany). Samples were processed within 3 h in order to minimize storage-dependent changes in cell volume, which affect haemoglobin concentration and hence analytic variability of the Hypo assay. This instrument, using¯ow cytometry, allows determination of volume and haemoglobin concentration of individual erythrocytes by measuring the amount of laser light scattered at two different angles from each spherical cell. Erythrocytes with haemoglobin concentration -28 gudl are considered to be hypochromic and values are expressed as percentages of total red blood cells (Hypo).
Reticulocytes, identi®ed by staining RNA with the dye oxazine, are measured for volume and haemoglobin concentration. The reticulocyte haemoglobin content (CHr) is calculated as the product of volume and haemoglobin concentration, providing the mean of the whole population.
Serum ferritin, iron, and transferrin were measured by enzyme-linked immunoadsorbent assay, by photometry with Ferene-S as a chromogen after reduction with ascorbic acid (Bayer Diagnostic, UK) and by immunonephelometry respectively. Transferrin saturation (TSat in %) was calculated as serum iron (mgudl) 3 70.9userum transferrin (mgudl).
Er-ZPP was measured by¯uorometry (Shimadzu, Rf-551) after erythrocyte lysis, deproteinization, extraction, and separation by high-performance liquid chromatography.
In a sub-population of 62 patients, serum sTf R levels were measured by a commercially available automated particle-enhanced immunonephelometric (PETIA) assay (Dade Behring, Marburg, Germany), using highly puri®ed sTf R isolated from human serum as a calibrator. This group of patients was not different from the total population in terms of sex distribution (35 males and 27 females), age (28±78 years), haemoglobin concentrations, Epo dose, or prevalence of ID (33.9 vs 40.8%, Psn.s.). Intra-and interassay variation coef®cients for all iron status laboratory indices were always less than 4%.
All markers of bone marrow iron supply showed good biological and analytical reproducibility with the following coef®cients of variation between values measured 2 days apart: CHr, 0.78"0.51% (ns30, range of values 24.9±34.1 pg); Er-ZPP, 3.63"1.54% (ns19, range of values 34±96 mmolumol haem); sTf R, 4.55"3.55% (ns21, range of values 0.86±2.59 mgul); and Hypo, 6.20"4.21% (ns62, range of values 2.5±14.7%). Figure 1 shows the amplitude of limits of agreement of the two repeated measurements for Hypo and CHr according to the Bland and Altman analysis.
Serum aluminium, intact PTH, folate, and vitamin B 12 concentrations were measured by atomic absorption spectrometry, immunoradiometry, and radioimmunoassay respectively.
C-reactive Protein (CRP) levels were assessed in 87 patients and were measured by a commercially available PETIA assay (Dade Behring, Marburg, Germany).
Study design
The haemoglobin response to approximately 1 g i.v. iron at constant doses of Epo was used as the reference standard for ID w2x and, as proposed by Allegra et al. w23x, subjects showing an increase in haemoglobin above or equal to 15% of baseline after i.v. iron were considered iron de®cient, while those with lesser or no change in haemoglobin were considered iron replete.
Iron was administered as a slow (over 2 min) bolus injection at the end of each dialysis session as sodium ferric gluconate complex in sucrose, which was the only available i.v. iron preparation at our institution. Since this preparation is unstable, showing rapid release of iron, we used a single dose of 31 or 62 mg iron in relation to predialysis serum transferrin levels (lower or higher than 170 mgudl respectively), to avoid the risk of oversaturation of transferrin and free iron' adverse reactions w24x.
This protocol was based on results from a preliminary study examining the relationship between predialysis serum transferrin levels, dose of i.v. iron, and TSat, evaluated 10 min after i.v. iron administration. This study showed that 62 mg iron was consistently associated with transferrin oversaturation in subjects with predialysis transferrin -170 mgudl (TSat 157.8"37.0% at serum transferrin 147"13 mgudl, ns6), but not in those with higher transferrin levels (TSat 78.5"14.1% at serum transferrin 209"31 mgudl, ns6). In contrast, the 31 mg dose did not lead to transferrin oversaturation at any transferrin level: TSat 62.3"17.5% at serum transferrin 209"32 mgudl (ns5) and 75.6"20.3% at serum transferrin 141"20 mgudl (ns6).
Haemoglobin and iron status indices, except Er-ZPP and sTfR, were evaluated every 2 weeks during the i.v. iron challenge period and treatment was continued until the end point for the diagnosis of ID was reached during at least two consecutive haemoglobin measurements, or if serum ferritin was above 600 nguml, a value associated with risk of iron overload, or if stable haemoglobin levels (i.e. less than 0.5 gudl difference in two consecutive measurements) were achieved after a minimum amount of 1023 mg i.v. iron.
This protocol, resulting from concerns to avoid adverse effects associated with i.v. sodium ferric gluconate complex administration w24x, could lead to differences in delivered iron and the length of the iron challenge period. However, this represents only a minor bias, since all subjects received at least 682 mg iron, an amount that is adequate for diagnostic purposes. In addition, frequent monitoring of haemoglobin levels allowed identi®cation of events other than iron load that may have affected haemoglobin, leading to exclusion of patients from the study.
The amount of supplied iron ranged from 682 to 1770 mg (median of 992 mg) over a treatment period ranging from 6 to 19 weeks (median of 8 weeks).
After iron withdrawal, we re-evaluated Er-ZPP and sTfR levels and assayed haemoglobin every 2 weeks for an additional 6 weeks, to identify late responders.
The Epo dose was held constant throughout the iron challenge period in all except ®ve patients, in whom it was halved due to brisk increase in haemoglobin. No adverse reactions were observed during the i.v. iron treatment period, except for a transient metallic taste reported by three patients.
Statistical analyses
To identify optimal tests and threshold values for predicting ID, receiver-operating characteristics (ROC) curve analysis was performed w25x by computing sensitivity and speci®city of the different tests at various cut-off levels. Sensitivity was de®ned as the percentage of patients with ID having a positive test (true positive, TP), and speci®city as the percentage of iron-replete patients having a negative test (true negative, TN). ROC curve analysis was performed by the Astute, DDU Software (The University of Leeds, UK). Diagnostic ef®ciency of different threshold levels, showing the probability that test and diagnosis agree, was calculated as the sum of TP and TN.
Since sensitivity, speci®city, and ef®ciency are uncalibrated measures of test performance, and random values are strongly dependent on prevalence and level of the test, we also calculated their calibrated values as measures of test quality, called`kappa coef®cients'; k(1,0) was the calibrated form of sensitivity, k(0,0) was the calibrated form of speci®city, and k(0.5,0) was the calibrated form of ef®ciency. Kappa coef®cients were calculated as follows: Multivariate regression analysis was performed to assess the predictive value of response to i.v. iron, the dose of Epo and amount of iron administered in the 6 months prior to the study. A stepwise discriminant function analysis was used to assess the diagnostic accuracy of the different tests and their associations. Data evaluation was carried out using the SPSS software package (SPSS Inc., Chicago, USA).
All data, based on single measurements, are expressed as means"standard deviation unless otherwise noted. Differences between groups were evaluated by non-parametric Mann±Whitney U test for the analysis of discrete variables, and a P value -0.05 was considered statistically signi®cant.
Results
After the i.v. iron challenge, 51 patients (40.8%) showed an increase in haemoglobin equal or higher than 15% from baseline, increasing by 1.86"0.49 gudl, and were considered iron de®cient (responders). The remaining 74 patients (59.2%) had no change or less than 15% increase from baseline haemoglobin, increasing by 0.43"0.34 gudl, and were considered iron replete (non-responders).
Responders and non-responders received the same median i.v. iron (990 mg, range 682±1440 mg, and 1020 mg, range 744 ±1770 mg respectively) over the same median period of time (7 weeks, range 6 ±12, and 8 weeks, range 6 ±19 weeks respectively). Table 1 summarizes baseline haemoglobin, Epo dose, and iron status markers in the two groups of patients. Responders had lower haemoglobin levels at higher Epo doses. They also showed lower ferritin, Tsat, and CHr, and higher Hypo, Er-ZPP and sTf R concentrations than non-responders. Both groups had a similar prevalence of patients with ferritin Figure 2 and Table 2 respectively. Haemoglobin signi®cantly increased in responders from the 4th week of treatment but did not change in non-responders.
Laboratory markers of iron status changed in the expected direction in responders, except for Er-ZPP, which did not change, while ferritin, Tsat, and CHr only increased in non-responders.
Responders and non-responders had a high prevalence of elevated CRP levels ()6 mgu l): 37.1% (13 of 35) and 26.9% (14 of 52) respectively. Subjects with normal and high CRP values had similar haemoglobin increases after the i.v. iron load in both responders (1.89"0.51 vs 1.79"0.5 gudl, Psn.s.) and non-responders (0.44"0.33 vs 0.42"0.34 gudl, Psn.s.). In addition, non-responders with normal and high CRP values had similar baseline haemoglobin, Epo dose, ferritin, TSat, Hypo, CHr, Er-ZPP, and sTf R (10.3"0.9 vs 10.4"0.9 gudl, 6236"2842 vs 6142"2656 uuweek, 198"112 vs 287"153 nguml, 24.8"8.6 vs 27.5"9.4%, 2.9"2.1 vs 3.0"1.0%, 31.4"1.9 vs 32.6"2.2 pg, 47.5"18.5 vs 45.2"13.1 mmolumol haem and 1.48"0.40 vs 1.34"0.21 mgul respectively).
The ROC curve analysis is shown in Figure 3 . All tests showed discriminative ability, with an area under the curve (W) signi®cantly different from 0.5. The test with the largest area under the curve was Hypo (Ws0.9296, SEs0.0233, P-0.0001), followed by CHr (Ws0.7976, SEs0.0425, P-0.0001), sTfR (Ws0.7834, SEs0.0591, P-0.0001), Er-ZPP (Ws0.7734, SEs0.0748, P-0.000), TSat (Ws0.7576, SEs0.0429, P-0.0001) and ferritin (Ws0.6329, SEs0.0605, P-0.05).
Statistically signi®cant differences between the area under the curve were observed for Hypo vs ferritin (P-0.001) and TSat (P-0.05), and for CHr vs Ferritin (P-0.05).
The best threshold values for detecting ID were )6% for Hypo, O29 pg for CHr, )1.5 mgul for sTf R, )52 mmolumol haem for Er-ZPP, -19% for TSat, and -50 nguml for ferritin.
Using multivariate regression analysis, the only signi®cant predictors of ID were Hypo (P-0.001) and the amount of i.v. iron administered in the 6 months prior to the study (P-0.05). Stepwise discriminant analysis showed Hypo to be the only test with an independent diagnostic value for ID (Wilks' lambda 0.611, Fs78.385, P-0.0001), being able to classify 87.2% of cases correctly.
In Table 3 , individual tests and their combinations that showed the best diagnostic performances are listed in hierarchical order, according to the calibrated value for ef®ciency, k(0.5,0). Data on the ef®ciency of the currently used cut-off levels of the various tests are also included.
A Hypo )6% was the best predictor of ID, either by itself or in combination with other tests. Its combination with CHr O29 pg produced a minor improvement in sensitivity and ef®ciency, while combination with TSat -19% and Er-ZPP )52 mmolumol haem produced a substantial increase in sensitivity, but at the expense of reduced speci®city and ef®ciency.
Discussion
Iron de®ciency has emerged as the major factor that limits response to Epo in haemodialysis patients, and aggressive treatment by i.v. iron has been advocated to optimize the use of the hormone w26x. This was con®rmed by our ®nding of a high prevalence of ID (approximately 41%) in an unselected population of haemodialysis patients on maintenance Epo who were non-aggressively and unevenly treated with i.v. iron on an as-needed basis according to low ferritin and TSat values. These patients showed hyporesponsiveness to the hormone and improvement in their haemoglobin levels by 1 to 3 gudl, after an average supplementation of 1 g i.v. iron.
Subclinical in¯ammatory states, as assessed by elevated CRP levels, did not appear to affect haemoglobin responses to i.v. iron in responders and nonresponders and therefore did not interfere with our diagnostic approach. In addition, the ®nding that responses to Epo and that levels of markers of iron utilization at the erythron were independent of CRP levels in non-responders, suggests that even in patients with increased CRP concentrations, the lack of haemoglobin response to i.v. iron is not the result of an in¯ammatory process, but instead may identify a state of iron repletion.
An accurate identi®cation of patients who will or will not respond to i.v. iron has relevant clinical and economical implications, since it allows improved response to Epo and avoidance of unnecessary risks associated with iron overload and overzealous therapy with parenteral iron w24x. Therefore, tests revealing threshold values with both acceptable sensitivity and acceptable speci®city, i.e. ef®cient tests, are required, and ef®ciency should be the primary selection criterion.
While there is consensus that conventional indices of iron status are poorly correlated to ID, the diagnostic role of the newer indices of iron availability to bone marrow and their relative ef®ciency and best cut-off values remain to be established. This is because studies evaluating diagnostic power are limited and have biased designs, including the choice of reference standard, sample size, and patient selection criteria.
Our study, which allowed a simultaneous evaluation of four established markers of iron supply to bone marrow (Hypo, CHr, Er-ZPP and sTf R) was adequate in size for proper statistical analysis and utilized a widely accepted`gold standard' for ID, should provide useful new information.
ROC curve analysis showed that all markers of iron status were able to discriminate iron-de®cient from iron-replete patients. Curve analysis also indicated a hierarchy of tests, with Hypo having the wider area under the curve followed by CHr, sTf R, Er-ZPP, TSat and ferritin.
The notion that Hypo is the most accurate marker was con®rmed by multivariate regression analysis as well as by stepwise discriminant regression analysis, which identi®ed this as the only variable with independent diagnostic value for ID with the ability to correctly classify 87% of the patients, indicating also that test combinations would not improve diagnostic performance.
Our data are in agreement with the recent European Best Practice Guidelines for the Management of Anemia in Patients with Chronic Renal Failure w5x, which favour Hypo as the best marker of iron-de®cient erythropoiesis. Indeed, Hypo was the only test that predicted the presence of ID with more than 80% certainty at cut-off values ranging from 4 to 8%. The best combination of sensitivity and speci®city was at a threshold )6% (k(0.5,0) 78.1%) instead of the currently accepted cut-off )10%, which showed absolute speci®city but unacceptably low sensitivity. Our results are in agreement with studies suggesting a better performance of Hypo at threshold levels -10%, in the range of 2.5±5% w6,7,9,18x. However, threshold values -6% allowed only modest increases in sensitivity at the expense of a marked decrease in speci®city.
The other markers of bone marrow iron availability showed similar diagnostic capacities with the most ef®cient threshold values signi®cantly lower than Hypo (k(0.5,0) ranging from 52.9 to 45.8%), including CHr, which has been proposed as the earliest and most sensitive marker for ID w9±11,20x.
In this study, CHr was a reliable marker of ID, but was inferior to Hypo even at its best cut-off value O29 pg (k(0,5,0) 52.9%, with low sensitivity and high speci®city). This is at variance with the reports by Fishbane et al. w10x and Cullen et al. w9x, who favoured CHr over Hypo. It should be noted that the results of these studies should be considered preliminary since the population sizes appeared insuf®cient for accurate statistical analysis. These differences can also be explained by the different criteria used to diagnose ID. Fishbane et al. w10x used an increase in corrected reticulocyte index of greater than 1 unit during 2 weeks after single dose i.v. iron infusion, and Cullen et al. w9x used TSat -15%. In contrast, we used the increase in haemoglobin after prolonged i.v. iron supply, which may identify different degrees anduor different stages of ID.
Our ®nding that the combination Hypo ) 6% or CHr O 29 pg showed the best ef®ciency value for ID (k(0.5,0) 80.0%, with an improvement in sensitivity compared to Hypo alone) suggests that the two tests, which can be performed simultaneously, can be considered complementary. Hypo, as an indicator of chronic iron requirements, may better apply to patients on steady-state erythropoietic stimulation, as in the present study, while CHr may be more useful in re¯ecting acute changes in iron availability.
Both sTf R and Er-ZPP had similar discriminative abilities for ID, and were slightly better than TSat. Our data con®rm that Er-ZPP has discriminative power (i.e. can be used as a marker) for ID during Epo treatment. Its best threshold value was )52 mmolumol haem, but it had no value that could be used to separate responders from non-responders, even over values ranging from 50 to 90 mmolumol haem (ef®-ciency ranging from 67.0 to 73.0%). This represents an important limitation to its utilization. In addition, its relative insensitivity to detect rapid changes in iron status was con®rmed by our ®nding of no change in Er-ZPP in iron-depleted patients after acute i.v. iron challenge.
The usefulness of Er-ZPP is improved when it is used in association with Hypo. The combination Hypo )6% or Er-ZPP )52 mmolumol haem signi®cantly increased the sensitivity of Hypo )6% (94.4%) but was associated with a substantial drop in speci®city (71.9%) and ef®ciency (80.0%). Similar but somewhat better diagnostic performances can be obtained by the association Hypo )6% or TSat -19%, which provides the highest sensitivity (96.1%). Both combinations of tests might be of value in clinical practice, where an optimally sensitive test is to be preferred. This is because the bene®ts of i.v. iron are well established whereas the risks linked to iron overload are still matters of debate.
Although others have suggested that sTf R is not a reliable marker of ID during Epo treatment w16x, our study showed this assay to have an acceptable discriminative ability, with the most ef®cient cut-off at sTf R )1.5 mgul (k(0.5,0) 47.3%). In our population of patients on maintenance erythropoietin, who are likely to be in steady-state erythropoietic stimulation, serum levels of sTfR may be useful in monitoring iron status. This conclusion is supported further by our ®nding of modest but signi®cant decreases in serum sTf R levels in iron-depleted patients after i.v. iron challenge. This result clearly favours sTf R over Er-ZPP. The Er ZPP test shows a similar diagnostic performance but is more inert than sTf R in detecting iron-status changes.
In addition, the association sTf R)1.5 mgul or TS at -19% had a high sensitivity (90.5%) in detecting ID with acceptable ef®ciency, indicating that this combination may be a useful tool in identifying patients who will respond to i.v. iron when erythrocyte and reticulocyte indices are not available. This combination is preferred over TSat, which even at the most ef®cient threshold value (TSat -19%) showed inadequate ef®ciency, sensitivity, and speci®city.
Our data con®rmed that ferritin predicts ID poorly, even at the best cut-off value of -50 nguml (k(0.5,0) 15.1%) and that the threshold values suggested by the NKF-DOQI guidelines for iron repletion therapy (ferritin -100 nguml and TSat -20%) w26x produced an unacceptably low accuracy for detecting responses to i.v. iron.
Since cost, availability, and reproducibility are also important for implementing tests in clinical practice, we evaluated the cost pro®le and both analytical and biological variability of the different markers. Hypo was the most convenient test. It was performed at no increased costs except for those of routine blood counts, whereas the other tests necessitated additional expenses (in Euros, 0.83 for CHr, 5.17 for sTf R, 7.69 for Er-ZPP, 10.48 for TSat, and 13.00 for ferritin).
All markers of iron supply to bone marrow showed good reproducibility. In our study, using fresh blood samples, CHr showed an extremely low coef®-cient of variation (mean value -1%), whereas Hypo, which has high variability when samples are stored for prolonged periods of time, showed an acceptable biological and analytical variability (coef®cient of variation 6.2%). The other tests had coef®ci-ents of variation less than 5%, indicating excellent reproducibility.
In conclusion, although all markers of iron status in haemodialysis patients on maintenance Epo show discriminative ability for iron-de®cient erythropoiesis, the best laboratory marker for those who will improve haemoglobin response after i.v. iron treatment, and who are hence considered iron de®cient, is Hypo at a threshold level )6%. Hypo demonstrated excellent diagnostic ef®ciency, inexpensiveness, and good reproducibility, indicating that it could be a ®rst-line test for monitoring iron requirements in clinical practice.
The diagnostic accuracy of Hypo can be slightly improved by simultaneous evaluation of CHr, which itself could be a suitable second choice because of its acceptable diagnostic accuracy, low cost, and high reproducibility.
When erythrocyte and reticulocyte assays are not available, sTfR and its combination with TSat appear to be useful alternatives.
